anti-doping is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-07-04. Numbers and descriptions here follow the published literature rather than marketing material.
Analytical identification and purity assessment often use high-performance liquid chromatography with ultraviolet detection or mass spectrometry. Liquid chromatography–tandem mass spectrometry is used to detect and quantify SR9009 in biological matrices, including urine and blood, for anti-doping or pharmacokinetic studies. Nuclear magnetic resonance spectroscopy can confirm molecular structure. Stability depends on form and storage: the solid is generally more stable than solutions, and repeated freeze–thaw cycles may degrade samples. Purity is typically reported as a percentage from a certificate of analysis.
Regulatory treatment of SR9009 varies by country and context. It is not approved as a therapeutic drug by agencies such as the United States Food and Drug Administration or the European Medicines Agency. Sports authorities list it as a prohibited substance; the World Anti-Doping Agency classifies it among hormone and metabolic modulators. Legal status for personal possession or sale differs across jurisdictions, and some countries may restrict it under analog or research chemical laws. Buyers who seek verified material often rely on independent laboratory testing because online product labels may not match contents.
Laboratory identification of SR9009 typically relies on chromatographic separation coupled to mass spectrometry, often with ultraviolet detection as a secondary check. Nuclear magnetic resonance spectroscopy can confirm molecular structure when a reference standard is available. Because many suppliers sell the compound as a research chemical, independent identity testing is important for experimental reproducibility. A single retention time is not sufficient proof of identity, especially when related compounds may be present. Purity assessments usually report a percentage based on area normalization.
SR9009 is generally described as poorly soluble in water and more soluble in organic solvents such as dimethyl sulfoxide and ethanol. Stock solutions are commonly prepared in an organic solvent before dilution into an aqueous buffer or vehicle. Precipitation can occur if the organic fraction is reduced too quickly or if the final concentration exceeds the compound's solubility limit. Sonication or gentle warming may aid dissolution in some protocols, but excessive heat can promote degradation. Container material and pH can also influence observed solubility.
For long-term storage, SR9009 is typically kept as a solid at low temperature, protected from moisture and light. Desiccated conditions limit hydrolysis, while opaque containers reduce photochemical breakdown. Solutions are less stable than solids and are often stored frozen in aliquots to avoid repeated freeze-thaw cycles. Stability data are not standardized across all suppliers, so users should rely on certificate-of-analysis information when available. Degradation may appear as color change, precipitate, or decreased chromatographic purity.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Common supplier description |
| Solubility | Soluble in DMSO and ethanol | Low solubility in water |
| Typical storage | −20 °C, desiccated, dark | For research samples |
| Analytical method | LC-MS/MS | Used for detection and quantification |
| Regulatory status | Prohibited in sport | WADA metabolic modulator class |
At the molecular level, SR9009 binds REV-ERBα and REV-ERBβ and alters their repressive activity on target genes. These nuclear receptors help regulate the circadian clock, lipid synthesis, glucose metabolism, and inflammatory pathways. By changing transcription, the compound can shift the timing or magnitude of downstream metabolic processes in model systems. It does not act through androgen receptors or adenosine receptors, which distinguishes it from several substances sold for athletic performance. Whether the same transcriptional changes occur in humans at tolerable exposures remains an open question because controlled human studies are lacking.
Preclinical reports describe effects on exercise endurance, mitochondrial content, and lipid profiles in rodents, but these findings come from specific experimental conditions. Many studies use high doses or delivery methods that may not translate directly to human use. SR9009 has been reported to have low oral bioavailability and a short half-life, which complicates interpretation of oral dosing studies. It is not established as safe or effective for any indication. Literature discussions often separate its pharmacological mechanism from unverified claims made in fitness and supplement markets.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not an approved medicine and has no established human therapeutic use. The compound appears in scientific literature as a tool for probing circadian and metabolic regulation. Online sellers often label it as a research chemical, sometimes using the nickname Stenabolic. Its chemical identity is distinct from selective androgen receptor modulators, stimulants, and peroxisome proliferator-activated receptor delta agonists. Researchers use it mainly in cell and animal experiments.
Handling recommendations for SR9009 in a laboratory setting include storing the solid at low temperature, protected from light and moisture. The compound is often dissolved in dimethyl sulfoxide or ethanol for experiments. Solutions should be prepared with appropriate personal protective equipment and disposed of according to local rules. Stability data for long-term storage are limited, so stock solutions are typically kept cold and used within defined periods. Records of preparation date and concentration support reproducibility.
SR9009 is not approved as a medicine by major regulatory agencies. It is commonly sold as a research chemical, a category that may fall outside customary drug approval and quality rules. In sports, the World Anti-Doping Agency lists SR9009 as a prohibited substance. Athletes who use it can face sanctions if it is detected in a sample. Legal status varies by country, and importation may be restricted. Enforcement practices differ across borders.
Detection of SR9009 in biological samples usually employs liquid chromatography coupled with tandem mass spectrometry. This method can identify the parent compound and sometimes metabolites in urine or blood. Because exposure can be low and clearance may be rapid, sample timing and limits of detection matter. Laboratories validate assays for sensitivity and specificity. Results are interpreted alongside chain-of-custody and quality-control records. Urine is the common matrix for anti-doping analysis, while blood may be used in research settings.
In 1995, Ice-T had a recurring role as vengeful drug dealer Danny Cort on the television series New York Undercover, co-created by Dick Wolf. His work on the series earned him the 1996 NAACP Image Award for Outstanding Supporting Actor in a Drama Series. In 1997, he co-created the short-lived series Players, produced by Wolf. This was followed by a role as pimp Seymour "Kingston" Stockton in Exiled: A Law & Order Movie (1998). These collaborations led Wolf to add Ice-T to the cast of Law & Order: Special Victims Unit. Since 2000, he has portrayed Odafin "Fin" Tutuola, a former undercover narcotics officer transferred to the Special Victims Unit. In 2002, the NAACP awarded Ice-T with a second Image Award, again for Outstanding Supporting Actor in a Drama Series, for his work on Law & Order: SVU. Around 1995, Ice-T co-presented a UK-produced magazine television series on black culture, Baadasss TV. In 1997, Ice-T had a pay-per-view special titled Ice-T's Extreme Babes which appeared on Action PPV, formerly owned by BET Networks. In 1999, Ice-T starred in the HBO film Stealth Fighter as a United States Naval Aviator who fakes his own death, steals an F-117 stealth fighter, and threatens to destroy United States military bases. He also acted in the film Sonic Impact, released the same year. Ice-T made an appearance on the comedy television series Chappelle's Show as himself presenting the award for "Player Hater of the Year" at the "Player-Haters Ball", a parody of his own appearance at the Players Ball. He was dubbed the "Original Player Hater".
This results from the elevated production of reactive oxygen species (ROS) that lead to oxidative DNA damage. Biochemical and cell-based assays demonstrated that the CUT domains within CUX1 and other Cut domain proteins stimulate the enzymatic activities of some enzymes of the base excision repair pathway and accelerate the repair of oxidative DNA damage. Hence, human and primary rodent fibroblasts that are transfected with KRAS and CUX1 exhibit similar ROS levels as cells that receive only KRAS but show much reduced DNA damage. In agreement with these findings, CUX1 knockdown is synthetic lethal in all cancer cells exhibiting high levels of ROS as a consequence of activating mutations in either KRAS, HRAS, BRAF or EGFR.
concentration The quantity or abundance of a constituent of a mixture per unit quantity of that mixture; e.g. the amount, in moles, of a dissolved solute per unit volume of a solution, a measure known as molar concentration or molarity. Several different definitions of concentration are widely used in chemistry, including molar concentration, mass concentration, and volume concentration.
Sources: en.wikipedia.org
=== Business === Protein Capture Science is a biotech start-up company commercializing a self-removing affinity tag technology for research and large-scale purifications of proteins. Wood and Izabela Gierach are co-founders of the company, based in Columbus, Ohio. The first line of the iCapTag products for protein purification was showcased in the Industry Innovators 2021-2022 Issue of the journal BioProcess International. Protein Capture Science was recently awarded several grants and funding, including highly competitive The Ohio Third Frontier Technology Validation and Start-Up Fund and the Concept Fund for extraordinary technologies by the Department of Development, State of Ohio.
==== Pharmacodynamics ==== In the context of pharmacodynamics (how the drug affects the body), the hydrophobic effect is the major driving force for the binding of drugs to their receptor targets. On the other hand, hydrophobic drugs tend to be more toxic because they, in general, are retained longer, have a wider distribution within the body (e.g., intracellular), are somewhat less selective in their binding to proteins, and finally are often extensively metabolized. In some cases the metabolites may be chemically reactive. Hence it is advisable to make the drug as hydrophilic as possible while it still retains adequate binding affinity to the therapeutic protein target. For cases where a drug reaches its target locations through passive mechanisms (i.e., diffusion through membranes), the ideal distribution coefficient for the drug is typically intermediate in value (neither too lipophilic, nor too hydrophilic); in cases where molecules reach their targets otherwise, no such generalization applies.
Most children with progeria appear normal at birth and during early infancy. Children with progeria usually develop the first symptoms during their first few months of life. The earliest symptoms may include a failure to thrive and a localized scleroderma-like skin condition. As a child ages past infancy, additional conditions become apparent, usually around 18–24 months. Limited growth, full-body alopecia (hair loss), and a distinctive appearance (a small face with a shallow, recessed jaw and a pinched nose) are all characteristics of progeria. Signs and symptoms of this progressive disease tend to become more marked as the child ages. Later, the condition causes wrinkled skin, kidney failure, loss of eyesight, and atherosclerosis and other cardiovascular problems. Scleroderma, a hardening and tightening of the skin on trunk and extremities of the body, is prevalent. People diagnosed with this disorder usually have small, fragile bodies, like those of older adults. The head is usually large relative to the body, with a narrow, wrinkled face and a beak nose. Prominent scalp veins are noticeable (made more obvious by alopecia), as well as prominent eyes. Musculoskeletal degeneration causes loss of body fat and muscle, stiff joints, hip dislocations, and other symptoms generally absent in the non-elderly population. Individuals usually retain typical mental and motor function.
On September 9, 2025, Talarico announced his candidacy for the 2026 U.S. Senate election in Texas. He and U.S. Representative Jasmine Crockett vied for the Democratic nomination. In February 2026, the Houston Chronicle, the Austin American-Statesman, The Dallas Morning News, and the Fort Worth Star-Telegram endorsed Talarico. Later in February, the FCC opened an investigation into Talarico's appearance on The View, citing a potential violation of the equal-time rule. Late-night and talk shows were exempt from the requirement until an FCC rule change in January 2026. On February 16, 2026, Talarico was scheduled to appear on The Late Show with Stephen Colbert. Colbert said CBS canceled the interview because of the Trump administration's "intensifying pressure against broadcast TV networks". He said the network's lawyers had instructed him not to have Talarico on the show or mention the cancellation. Against their advice, he interviewed Talarico and spoke publicly about the cancellation. Colbert accused CBS of censorship and posted the interview to the show's YouTube page instead, where it had gained 7.3 million views by February 18, making it the most viewed interview segment on The Late Show's channel in a year. On March 3, Talarico won the Democratic primary, securing the party's nomination in the November general election. In the general election, he faces Texas Attorney General Ken Paxton, who won the Republican primary runoff on May 26. Former President Barack Obama appeared at an event with Talarico in May 2026.
Sources: en.wikipedia.org
Legality depends on the country and the intended use. In many places it is sold as a research chemical, but sports and medicine regulations restrict it.
Detection commonly uses liquid chromatography–tandem mass spectrometry. This method can identify the compound in urine or blood at low concentrations.
Typical guidance is −20 °C, dry, and protected from light. Solutions should be aliquoted and limited freeze–thaw cycles should be used.
Liquid chromatography with mass spectrometry is a common approach. Ultraviolet detection and nuclear magnetic resonance can support identification when suitable standards are available.